
Advanced Production Infrastructure for Diverse Formats & Biomaterials
Precision production capability built on diverse biomaterials and state-of-the-art smart equipment
We operate a customized production infrastructure that fully realizes a wide range of polymer and bio raw materials — HA, PN, CaHA, PLA/PDLLA, rH COL III (collagen), exosomes, and various novel materials. With dedicated smart equipment and aseptic filling systems optimized for each format — syringe, vial, and lyophilized — we guarantee a large-scale, stable supply of over 24 million units per year.
Production Lines

Syringe Production Line
- Annual CAPA: 12 million units per year (1 mL basis)
- Target Formats: HA, PN, CaHA, HA Hybrid
- Key Features: Precision filling technology for high-viscosity elastic materials and an autoclave sterilization system to maintain complete asepsis

Vial Production Line
- Annual CAPA: 11 million units per year (5 mL basis)
- Target Formats: PN, Exosome, Collagen, NAD+
- Key Features: A fully integrated automated line — washing, tunnel sterilization, filling, lyophilization, and cap sealing — ensures high-quality, repeatable productivity

Lyophilization Production Line
- Annual CAPA: 1.2 million units per year (PDLLA 200 mg basis)
- Target Formats: PLA fillers and skin boosters
- Key Features: Particle homogenization via membrane emulsification, particle lyophilization, precision count filling, and linked EO gas sterilization
Packaging System
High-Speed Automated Packaging
A precision automation system linked from labeling through PTP blister forming, sealing, cartoning, and wrapping secures consistency and high productivity in mass production.
Flexible Manual Packaging
A dedicated manual packaging system runs in parallel to respond quickly to small-batch, multi-product orders and partner-specific packaging specifications.
Reanzen Product Inquiry.
Explore Reanzen's full product lineup
